LASANTH

WIPO WIPO 2021

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark LASANTH was filed as Word mark on 04/02/2021 at the World Intellectual Property Organization.

Trademark Details Last update: March 28, 2023

Trademark form Word mark
File reference 1610291
Countries China em United Kingdom Israel India Japan South Korea
Base trademark US No. 90236132, October 5, 2020
Application date April 2, 2021
Expiration date April 2, 2031

Trademark owner

48 Holland Brook Road
Whitehouse Station NJ 08889
US

Trademark representatives

1299 Pennsylvania Avenue, Suite 700 Washington DC 20004 US

goods and services

35 Business consulting services in the field of regulatory and corporate compliance; business development services; business strategy development services; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, pharmaceutical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; regulatory submission management, namely, assisting others in preparing and filing applications for new medical devices, medical technologies, medications, pharmaceutical, biopharmaceuticals, and biotechnology with governmental regulatory bodies around the world; regulatory submission management, namely, providing simultaneous multiple country submissions of applications for the registration and approval of medical devices, medical technologies, medications, pharmaceutical, biopharmaceuticals, and biotechnology; providing business information online regarding regulatory submission management; business management consulting, strategic planning and business advisory services provided to medical, medical technology, pharmaceutical, biopharmaceutical, and biotechnology companies, and government agencies, educational and research institutions, law firms, and investment firms in the fields of biologics, pharmaceuticals and medical devices; providing consulting services in the field of regulatory submission management to medical companies to assist them with applications for drug and medical device approval; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs and medical devices with governmental regulatory bodies; business consulting services in the field of biologics, pharmaceuticals, prescription drugs and medical devices
42 Consulting services for others in the field of designing pre-clinical and clinical studies and trials for others; product research and development for others in the fields of biologics, pharmaceuticals, prescription drugs and medical devices; quality management services, namely, quality evaluation and analysis, quality assurance and quality control in the field of biologics, pharmaceuticals, prescription drugs and medical devices; scientific consulting and research services relating to the field of pharmaceuticals, medical devices, and life sciences, namely, biology, and medicine; consulting services in the fields of biotechnology and pharmaceuticals, namely, design, development, technical verification and technical validation of manufacturing and filling processes, drug formulations, testing protocols and analytical methods; and scientific and technological services, namely, scientific research, analysis, testing, and related scientific studies in the field of chemistry and molecular biology, namely, biologics and protein detection, characterization, analysis and testing; consulting services in the field of product quality approval for medical devices for commercial purposes
45 Regulatory compliance consulting services, namely, reviewing standards and practices to assist clients with compliance with governmental laws, regulations and rules in the fields of medical devices, medical technologies, medications, biopharmaceuticals, and biotechnology; providing technical regulatory affair consulting services directed to medical, medical technology, biopharmaceutical, and biotechnology companies in order to assure compliance with food and drug administration's laws and regulations; provision of information online pertaining to regulatory compliance in the fields of medical devices, medical technologies, medications, biopharmaceuticals, and biotechnology; and regulatory compliance consulting in the fields of biologics, pharmaceuticals, prescription drugs and medical devices

Trademark history

Date Document number Area Entry
March 23, 2023 2023/13 Gaz KR RAW: Rule 18ter(2)(ii) GP following a provisional refusal
February 23, 2023 2023/8 Gaz JP RAW: Rule 18ter(2)(i) GP following a provisional refusal
October 17, 2022 2022/42 Gaz KR Rejection
September 1, 2022 2022/40 Gaz RAW: Limitation
June 2, 2022 2022/22 Gaz JP Rejection
May 2, 2022 2022/19 Gaz IL Rejection
February 15, 2022 2022/7 Gaz IN Rejection
January 19, 2022 2022/3 Gaz EM Rejection
January 5, 2022 2022/1 Gaz GB Rejection
January 4, 2022 2022/1 Gaz CN Rejection
April 2, 2021 2021/33 Gaz US Registration

ID: 141610291